Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)
Status:
Not yet recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
The neoCARHP study was a randomized, open-label, multicenter, phase III, neoadjuvant trial.
This study aimed to compare the efficacy and safety of
docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) with docetaxel/trastuzumab/pertuzumab
(THP) neoadjuvant setting for HER2-positive breast cancer. Patients will be randomized at a
1:1 ratio into TCHP or THP, respectively, and will be treated every 3 weeks before
surgery.The primary endpoint was the percentage of pCR (ypT0/is, ypN0), which was defined as
the absence of any residual invasive cancer in both the breast and axillary lymph nodes.